XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Subscribe To Our Newsletter & Stay Updated
